Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.99 USD | +0.97% | +4.88% | -8.60% |
May. 07 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
May. 01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The stock, which is currently worth 2024 to 0.64 times its sales, is clearly overvalued in comparison with peers.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.60% | 933M | C+ | ||
+16.86% | 8.43B | D+ | ||
+5.05% | 7.49B | C- | ||
+4.89% | 6.23B | - | ||
-5.23% | 3.75B | B- | ||
-6.58% | 3.75B | D | ||
-3.55% | 1.33B | - | - | |
-28.64% | 1.09B | B+ | ||
+18.12% | 1.02B | - | ||
-17.08% | 801M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- USNA Stock
- Ratings USANA Health Sciences, Inc.